Nadine Haddad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nadine Haddad has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Majd Saleh
London School of Hygiene and Tropical Medicine, Department of Global Health and Development, 15–17 Tavistock Place, London WC1H 9SH, UK
2 shared publications - Nada Ghosn
Epidemiological Surveillance Program, Ministry of Public Health, Beirut 0127, Lebanon
2 shared publications - Pamela Mrad
Lebanon Country Office, World Health Organization, Beirut 2832, Lebanon
2 shared publications - Zeina Farah
Epidemiological Surveillance Program, Lebanon Ministry of Public Health, Beirut, Lebanon
2 shared publications - Ahmed Abdulgadir Noureddin
Faculty of Medicine, University of Khartoum, Khartoum, Sudan
1 shared publication - Baha Aldeen Alshareif
Department of Surgery, Faculty of Medicine, Alzaiem Alazhari University, Khartoum, Sudan
1 shared publication
Latest Publications
- Open Access
- 14 March 2026
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Suboptimal uptake of the malaria vaccine in Sudan: what's behind the blinds?
Malaria is a public health problem in Sudan, with more than 89% of cases caused by Plasmodium falciparum. In 2024 Sudan introduced R21/Matrix-M malaria vac
- 14 March 2026
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Open AccessSuboptimal uptake of the malaria vaccine in Sudan: what's behind the blinds?
Malaria is a public health problem in Sudan, with more than 89% of cases caused by Plasmodium falciparum. In 2024 Sudan introduced R21/Matrix-M malaria vac
- Open Access
- 22 January 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-29
Burden of pertussis in infants in the Eastern Mediterranean Region and the impact of maternal vaccination: a systematic review
Despite vaccine availability, Pertussis remains a global public health challenge, especially among infants. The Eastern Mediterranean Region (EMR) presents a diverse epidemiological landscape with varying vaccination coverages and healthcare infrastructures. This systematic review aimed to assess the burden of pertussis in infants < 1 year of age in the EMR and evaluate the use and impact of pertussis vaccination during pregnancy. Following PRISMA guidelines, we conducted a systematic search of Scopus, Embase, CINAHL Ultimate, and PubMed from inception until April 30, 2024. Studies included reported on pertussis burden in infants or maternal vaccination. Data extraction and quality assessment were performed in duplicate, focusing on incidence, age distribution, disease severity, and vaccination uptake and impact when data were available. Thirty-six studies were included, the majority from Iran (N = 11), Morocco (N = 5), Tunisia (N = 5), and Oman (N = 3), with underrepresentation of other EMR countries. The incidence of PCR-confirmed pertussis among children with suspected pertussis varied significantly, from 6.7% to 8.9% (Morocco 2018–2019) to 50.4% and 51.6% (Palestine 2004–2008) among children < 12 and < 6 months, respectively, and between 16.3% (Tunisia 2007–2016) to 73.0% (Morocco 2013–2015) in children < 2 months. Age distribution data indicated the highest burden was in infants < 2 months regardless of the population studied. High hospitalization rates and severe complications, including seizures and the need for ventilatory support, were frequently reported in infants < 6 months of age. Only one study from Saudi Arabia addressed maternal pertussis vaccination, reflecting low vaccine uptake and awareness among pregnant women. This review underscores the substantial burden of pertussis among infants in the EMR and the lack of data on maternal immunization. The findings emphasize the need for enhanced surveillance and targeted public health interventions to reduce disease incidence. Future research should prioritize underrepresented countries to ensure comprehensive data for informed public health strategies. PROSPERO (CRD42024573471)
- 22 January 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-29
Open AccessBurden of pertussis in infants in the Eastern Mediterranean Region and the impact of maternal vaccination: a systematic review
Despite vaccine availability, Pertussis remains a global public health challenge, especially among infants. The Eastern Mediterranean Region (EMR) presents a diverse epidemiological landscape with varying vaccination coverages and healthcare infrastructures. This systematic review aimed to assess the burden of pertussis in infants < 1 year of age in the EMR and evaluate the use and impact of pertussis vaccination during pregnancy. Following PRISMA guidelines, we conducted a systematic search of Scopus, Embase, CINAHL Ultimate, and PubMed from inception until April 30, 2024. Studies included reported on pertussis burden in infants or maternal vaccination. Data extraction and quality assessment were performed in duplicate, focusing on incidence, age distribution, disease severity, and vaccination uptake and impact when data were available. Thirty-six studies were included, the majority from Iran (N = 11), Morocco (N = 5), Tunisia (N = 5), and Oman (N = 3), with underrepresentation of other EMR countries. The incidence of PCR-confirmed pertussis among children with suspected pertussis varied significantly, from 6.7% to 8.9% (Morocco 2018–2019) to 50.4% and 51.6% (Palestine 2004–2008) among children < 12 and < 6 months, respectively, and between 16.3% (Tunisia 2007–2016) to 73.0% (Morocco 2013–2015) in children < 2 months. Age distribution data indicated the highest burden was in infants < 2 months regardless of the population studied. High hospitalization rates and severe complications, including seizures and the need for ventilatory support, were frequently reported in infants < 6 months of age. Only one study from Saudi Arabia addressed maternal pertussis vaccination, reflecting low vaccine uptake and awareness among pregnant women. This review underscores the substantial burden of pertussis among infants in the EMR and the lack of data on maternal immunization. The findings emphasize the need for enhanced surveillance and targeted public health interventions to reduce disease incidence. Future research should prioritize underrepresented countries to ensure comprehensive data for informed public health strategies. PROSPERO (CRD42024573471)
- Open Access
Effectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults ≥75 years- Lebanon, April-May 2021
Introduction In Lebanon, the nationwide vaccination against COVID-19 was launched in February-2021 using Pfizer-BioNTech vaccine and prioritizing elderly, persons with comorbidities and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of Pfizer-BioNTech in preventing COVID-19 hospitalization among ≥75 years in Lebanon. Methods A case-control study design was used. Cases were Lebanese, ≥75 years and hospitalized with positive PCR result during April-May 2021. Cases were randomly selected from the COVID-19 database of the Epidemiological Surveillance Unit(ESU) at the Ministry of Public Health(MOPH). Each case was matched by age and locality to 2 controls. Controls were hospitalized, non-COVID-19 patients with negative PCR result, randomly selected from the MOPH hospital admission database. VE was calculated for fully and partially vaccinated, using multivariate conditional logistic regression analyses. Results 345 cases and 814 controls were recruited. Half were females, with a mean age of 83 years. 14 cases(5%) and 143 controls(22%) were fully vaccinated. Bivariate analysis showed significant association with: gender, month of confirmation/admission, general health, chronic medical conditions, main income source and living arrangement. After adjusting for month of admission and gender, multivariate analysis yielded a VE of 82% (95%CI = 69%-90%) against COVID-19 associated hospitalization for those fully vaccinated and 53% (95%CI = 23%-71%) for those partially vaccinated (≥14 days of first or within 14 days of second dose). Conclusions Our study showed that Pfizer-BioNTech vaccine is effective in reducing risk for COVID-19– associated hospitalization in Lebanese elderly(≥75 years). Additional studies are warranted to explore vaccine effectiveness in reducing hospitalization in younger age groups, as well as in reducing covid-19 infections.
Open AccessEffectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults ≥75 years- Lebanon, April-May 2021
Introduction In Lebanon, the nationwide vaccination against COVID-19 was launched in February-2021 using Pfizer-BioNTech vaccine and prioritizing elderly, persons with comorbidities and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of Pfizer-BioNTech in preventing COVID-19 hospitalization among ≥75 years in Lebanon. Methods A case-control study design was used. Cases were Lebanese, ≥75 years and hospitalized with positive PCR result during April-May 2021. Cases were randomly selected from the COVID-19 database of the Epidemiological Surveillance Unit(ESU) at the Ministry of Public Health(MOPH). Each case was matched by age and locality to 2 controls. Controls were hospitalized, non-COVID-19 patients with negative PCR result, randomly selected from the MOPH hospital admission database. VE was calculated for fully and partially vaccinated, using multivariate conditional logistic regression analyses. Results 345 cases and 814 controls were recruited. Half were females, with a mean age of 83 years. 14 cases(5%) and 143 controls(22%) were fully vaccinated. Bivariate analysis showed significant association with: gender, month of confirmation/admission, general health, chronic medical conditions, main income source and living arrangement. After adjusting for month of admission and gender, multivariate analysis yielded a VE of 82% (95%CI = 69%-90%) against COVID-19 associated hospitalization for those fully vaccinated and 53% (95%CI = 23%-71%) for those partially vaccinated (≥14 days of first or within 14 days of second dose). Conclusions Our study showed that Pfizer-BioNTech vaccine is effective in reducing risk for COVID-19– associated hospitalization in Lebanese elderly(≥75 years). Additional studies are warranted to explore vaccine effectiveness in reducing hospitalization in younger age groups, as well as in reducing covid-19 infections.
- Open Access
- 11 October 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-6
Calculating the serial interval of SARS-CoV-2 in Lebanon using 2020 contact-tracing data
Introduction: The first detected case in Lebanon on 21 February 2020 engendered implementation of a nationwide lockdown alongside timely contact-tracing and testing. Objectives: Our study aims to calculate the serial interval of SARS-CoV-2 using contact tracing data collected 21 February to 30 June 2020 in Lebanon to guide testing strategies. Methods: rRT-PCR positive COVID-19 cases reported to the Ministry of Public Health Epidemiological Surveillance Program (ESU-MOH) are rapidly investigated and identified contacts tested. Positive cases and contacts assigned into chains of transmission during the study time-period were verified to identify those symptomatic, with non-missing date-of-onset and reported source of exposure. Selected cases were classified in infector–infectee pairs. We calculated mean and standard deviation for the serial interval and best distribution fit using AIC criterion. Results: Of a total 1788 positive cases reported, we included 103 pairs belonging to 24 chains of transmissions. Most cases were Lebanese (98%) and male (63%). All infectees acquired infection locally. Mean serial interval was 5.24 days, with a standard deviation of 3.96 and a range of − 4 to 16 days. Normal distribution was an acceptable fit for our non-truncated data. Conclusion: Timely investigation and social restriction measures limited recall and reporting biases. Pre-symptomatic transmission up to 4 days prior to symptoms onset was documented among close contacts. Our SI estimates, in line with international literature, provided crucial information that fed into national contact tracing measures. Our study, demonstrating the value of contact-tracing data for evidence-based response planning, can help inform national responses in other countries.
- 11 October 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-6
Open AccessCalculating the serial interval of SARS-CoV-2 in Lebanon using 2020 contact-tracing data
Introduction: The first detected case in Lebanon on 21 February 2020 engendered implementation of a nationwide lockdown alongside timely contact-tracing and testing. Objectives: Our study aims to calculate the serial interval of SARS-CoV-2 using contact tracing data collected 21 February to 30 June 2020 in Lebanon to guide testing strategies. Methods: rRT-PCR positive COVID-19 cases reported to the Ministry of Public Health Epidemiological Surveillance Program (ESU-MOH) are rapidly investigated and identified contacts tested. Positive cases and contacts assigned into chains of transmission during the study time-period were verified to identify those symptomatic, with non-missing date-of-onset and reported source of exposure. Selected cases were classified in infector–infectee pairs. We calculated mean and standard deviation for the serial interval and best distribution fit using AIC criterion. Results: Of a total 1788 positive cases reported, we included 103 pairs belonging to 24 chains of transmissions. Most cases were Lebanese (98%) and male (63%). All infectees acquired infection locally. Mean serial interval was 5.24 days, with a standard deviation of 3.96 and a range of − 4 to 16 days. Normal distribution was an acceptable fit for our non-truncated data. Conclusion: Timely investigation and social restriction measures limited recall and reporting biases. Pre-symptomatic transmission up to 4 days prior to symptoms onset was documented among close contacts. Our SI estimates, in line with international literature, provided crucial information that fed into national contact tracing measures. Our study, demonstrating the value of contact-tracing data for evidence-based response planning, can help inform national responses in other countries.